AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34244750 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without clinical pharmacist's interventions
Number of subjects: 256
Study 32816144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest (COLD)
Number of subjects: 10
Study 33739404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd-R (lenalidomide 10 mg per day without dexamethasone)
Number of subjects: 199
Study 33739404 — intervention group
Group type: COMPARATOR
Intervention: Continuous Rd
Number of subjects: 199
Study 33739404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd-R
Number of subjects: 199
Study 35668682 — intervention group
Group type: EXPERIMENTAL
Intervention: M. alternifolia pure essential oil
Number of subjects: 40
Study 35668682 — intervention group
Group type: EXPERIMENTAL
Intervention: M. alternifolia Nanoemulsion
Number of subjects: 40
Study 35668682 — intervention group
Group type: COMPARATOR
Intervention: Vehicle formulation
Number of subjects: 40
Study 34313609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (n=23)
Number of subjects: 50
Study 34313609 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (n=23)
Number of subjects: 50
Study 32805259 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 116
Study 32805259 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 116
Study 32805259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NAS severity cluster
Number of subjects: 116
Study 32805259 — intervention group
Group type: EXPERIMENTAL
Intervention: High NAS severity cluster
Number of subjects: 116
Study 35546664 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (albiglutide, exenatide, liraglutide, semaglutide, lixisenatide, dulaglutide)
Number of subjects: 52821
Study 35546664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52821
Study 32748415 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and psychological abuse exposure
Number of subjects: 600
Study 32748415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple forms of abuse (physical and psychological) exposure
Number of subjects: 600
Study 32748415 — intervention group
Group type: COMPARATOR
Intervention: Non-abused controls
Number of subjects: 600
Study 32236398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice wine lees (RWL)
Number of subjects: 35
Study 32236398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 36087550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 and 300 mg every 2 weeks
Number of subjects: 0
Study 36087550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33929326 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program about best practice knee OA management via telehealth delivery
Number of subjects: 15
Study 33929326 — intervention group
Group type: EXPERIMENTAL
Intervention: mock video consultation with a researcher and 4 audited practice video consultations with pilot patients
Number of subjects: 15
Study 33929326 — intervention group
Group type: EXPERIMENTAL
Intervention: self-directed learning modules
Number of subjects: 15
Study 33929326 — intervention group
Group type: EXPERIMENTAL
Intervention: overall e-learning program
Number of subjects: 15
Study 33929326 — intervention group
Group type: EXPERIMENTAL
Intervention: training program
Number of subjects: 15
Study 33166722 — intervention group
Group type: EXPERIMENTAL
Intervention: pegilodecakin + pembrolizumab
Number of subjects: 153
Study 33166722 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 153
Study 33166722 — intervention group
Group type: EXPERIMENTAL
Intervention: pegilodecakin + nivolumab
Number of subjects: 153
Study 33166722 — intervention group
Group type: COMPARATOR
Intervention: nivolumab
Number of subjects: 153
Study 32375735 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery followed by systemic therapy
Number of subjects: 90
Study 32375735 — intervention group
Group type: COMPARATOR
Intervention: Primary systemic therapy without surgery
Number of subjects: 90
Study 32375735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 32375735 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women in both groups
Number of subjects: 90
Study 32375735 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline global health status and physical functioning
Number of subjects: 90
Study 32375735 — intervention group
Group type: EXPERIMENTAL
Intervention: Global health status, social functioning scale, breast symptoms and future perspective
Number of subjects: 90
Study 36378077 — intervention group
Group type: EXPERIMENTAL
Intervention: 150iu BD of formulated regular insulin in enteric-coated capsules
Number of subjects: 100
Study 36378077 — intervention group
Group type: COMPARATOR
Intervention: 75iu BD of formulated regular insulin in enteric-coated capsules
Number of subjects: 100
Study 36378077 — intervention group
Group type: COMPARATOR
Intervention: 300iu BD of formulated regular insulin in enteric-coated capsules
Number of subjects: 100
Study 36378077 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 100
Study 32698233 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 334
Study 32698233 — intervention group
Group type: COMPARATOR
Intervention: Lugol chromoendoscopy
Number of subjects: 334
Study 32504694 — intervention group
Group type: EXPERIMENTAL
Intervention: 48‐h zero‐calorie diet with water provided ad libitum
Number of subjects: 11
Study 32504694 — intervention group
Group type: COMPARATOR
Intervention: 48‐h usual diet
Number of subjects: 11
Study 35758031 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (300 mg daily)
Number of subjects: 22
Study 35758031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34136900 — intervention group
Group type: EXPERIMENTAL
Intervention: STIMULAX (oral Coloxyl® with senna and macrogol, with sodium phosphate enema for right-sided operations)
Number of subjects: 170
Study 34136900 — intervention group
Group type: COMPARATOR
Intervention: Control (standard ERP postoperative care)
Number of subjects: 170
Study 35544473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid/insulin infusion
Number of subjects: 12
Study 35544473 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 33206462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (25 mg)
Number of subjects: 2629
Study 33206462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2629
Study 36063401 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized instructions for TKV measurement
Number of subjects: 49
Study 36063401 — intervention group
Group type: COMPARATOR
Intervention: Non-standardized instructions for TKV measurement
Number of subjects: 49
Study 33074326 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 573
Study 33074326 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 with bevacizumab
Number of subjects: 573
Study 33074326 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX with bevacizumab
Number of subjects: 573
Study 35965453 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program in addition to standard care
Number of subjects: 64
Study 35965453 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 64
Study 33319454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 0
Study 33319454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32464224 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-volume feedings (180-200 mL/kg/d)
Number of subjects: 224
Study 32464224 — intervention group
Group type: COMPARATOR
Intervention: Usual-volume feedings (140-160 mL/kg/d)
Number of subjects: 224
Study 33951510 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-affective skills training (Affect module)
Number of subjects: 332
Study 33951510 — intervention group
Group type: COMPARATOR
Intervention: Attention and interoceptive awareness training (Presence module)
Number of subjects: 332
Study 33951510 — intervention group
Group type: COMPARATOR
Intervention: Socio-cognitive skills training (Perspective module)
Number of subjects: 332
Study 32078754 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology performed three times per day at every eight hours for 30 min for 3 days
Number of subjects: 100
Study 32078754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 100
Study 32078754 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 100
Study 35906606 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended training (online and face-to-face)
Number of subjects: 20
Study 35906606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study 33741284 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge (Collacone)
Number of subjects: 23
Study 33741284 — intervention group
Group type: COMPARATOR
Intervention: Empty alveolus (control)
Number of subjects: 23
Study 32701480 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education provided on the third day after MI, sessions lasted 90 to 120 minutes
Number of subjects: 70
Study 32701480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer education)
Number of subjects: 70
Study 35898121 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction during venous cannulation
Number of subjects: 106
Study 35898121 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (topical numbing cream, positioning, and distraction by games on tablet/smartphone)
Number of subjects: 106
Study 35898121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VR and control)
Number of subjects: 106
Study 34678198 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Number of subjects: 20019
Study 34678198 — intervention group
Group type: COMPARATOR
Intervention: Capsular group A meningococcal conjugate vaccine (MenA)
Number of subjects: 20019
Study 34561291 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-directed treatment adjustment
Number of subjects: 291
Study 34561291 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 291
Study 34561291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition onto or off oral corticosteroids
Number of subjects: 291
Study 34561291 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency room attendance in the prior year
Number of subjects: 291
Study 34561291 — intervention group
Group type: EXPERIMENTAL
Intervention: Belonging to an ethnic minority group
Number of subjects: 291
Study 34561291 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior study medication changes (two or more changes)
Number of subjects: 291
Study 35797682 — intervention group
Group type: COMPARATOR
Intervention: Home Stretching (HS)
Number of subjects: 57
Study 35797682 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 57
Study 33412106 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 200/31·25/25 μg
Number of subjects: 748
Study 33412106 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 200/25 μg
Number of subjects: 748
Study 32657376 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniception randomized algorithm
Number of subjects: 0
Study 32657376 — intervention group
Group type: COMPARATOR
Intervention: Random minimizer
Number of subjects: 0
Study 33608147 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior musical experience
Number of subjects: 51
Study 33608147 — intervention group
Group type: COMPARATOR
Intervention: Nonmusicians
Number of subjects: 51
Study 32858229 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 144
Study 32858229 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training alone
Number of subjects: 144
Study 33398056 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 986
Study 33398056 — intervention group
Group type: EXPERIMENTAL
Intervention: Penta 1 vaccination
Number of subjects: 986
Study 33398056 — intervention group
Group type: EXPERIMENTAL
Intervention: Penta 3 vaccination
Number of subjects: 986
Study 32994178 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic method
Number of subjects: 52
Study 32994178 — intervention group
Group type: COMPARATOR
Intervention: Blind method
Number of subjects: 52
Study 36061400 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine‐propofol (sketofol) group
Number of subjects: 66
Study 36061400 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 66
Study 33411341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor-implemented violence prevention program (Take Charge!)
Number of subjects: 98
Study 32437569 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of physical activity (PA)
Number of subjects: 3050
Study 35599183 — intervention group
Group type: EXPERIMENTAL
Intervention: mTESE
Number of subjects: 100
Study 35599183 — intervention group
Group type: COMPARATOR
Intervention: multiple needle‐pass TESA
Number of subjects: 100
Study 35599183 — intervention group
Group type: COMPARATOR
Intervention: multiple needle‐pass TESA + salvage mTESE
Number of subjects: 100
Study 35599183 — intervention group
Group type: EXPERIMENTAL
Intervention: mTESE and multiple needle‐pass TESA
Number of subjects: 100
Study 34289996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASyMS (intervention; n=415)
Number of subjects: 829
Study 34289996 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control; n=414)
Number of subjects: 829
Study 34289996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASyMS
Number of subjects: 829
Study 32107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain scores on POD1
Number of subjects: 160
Study 32107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain scores on POD2
Number of subjects: 160
Study 32107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Unacceptable pain (NRS ≥ 6) on POD1
Number of subjects: 160
Study 32107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Unacceptable pain (NRS ≥ 6) on POD2
Number of subjects: 160
Study 32107359 — intervention group
Group type: EXPERIMENTAL
Intervention: Unacceptable pain (NRS ≥ 6) on POD2 as a predictor
Number of subjects: 160
Study 36208097 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day azacitidine (AZA)
Number of subjects: 55
Study 36208097 — intervention group
Group type: COMPARATOR
Intervention: 7-day azacitidine (AZA)
Number of subjects: 55
Study 33040598 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated programme (a pre-admission day, two weeks at home, two weeks inpatient followed by home-based activities, plus two 2-day inpatient booster sessions, and six-month follow-up visit)
Number of subjects: 165
Study 33040598 — intervention group
Group type: COMPARATOR
Intervention: Existing programme (four-week inpatient, and six-month follow-up visit)
Number of subjects: 165
Study 32203980 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox dispersible tablets (10 to 40 mg/kg per day)
Number of subjects: 225
Study 32203980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 32203980 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 225
Study 34105208 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive e‐cigarette users
Number of subjects: 114
Study 34105208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual users
Number of subjects: 114
Study 34105208 — intervention group
Group type: COMPARATOR
Intervention: Exclusive smokers
Number of subjects: 114
Study 32798567 — intervention group
Group type: EXPERIMENTAL
Intervention: High early parenteral soybean oil lipid intake starting at 2 g/kg per day, increasing to 3 g/kg per day the following day.
Number of subjects: 83
Study 32798567 — intervention group
Group type: COMPARATOR
Intervention: Control group started at 0.5-1 g/kg per day, increasing daily by 0.5-1 g/kg per day till reaching 3 g/kg per day.
Number of subjects: 83
Study 34319571 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater sleep disturbance
Number of subjects: 302
Study 34319571 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination
Number of subjects: 302
Study 34319571 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stressors
Number of subjects: 302
Study 34319571 — intervention group
Group type: EXPERIMENTAL
Intervention: Good sleep
Number of subjects: 302
Study 32060825 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Pongamia pinnata shells (NPP)
Number of subjects: 0
Study 32060825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid-activated Pongamia pinnata shells (PPP)
Number of subjects: 0
Study 32060825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphuric acid-activated Pongamia pinnata shells (SPP)
Number of subjects: 0
Study 34255087 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizationally tailored approach
Number of subjects: 14
Study 34255087 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (core components only)
Number of subjects: 14
Study 34220819 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevenar13® (PCV13)
Number of subjects: 225
Study 34220819 — intervention group
Group type: COMPARATOR
Intervention: Haemophilus influenzae‐type b (Hib) vaccine
Number of subjects: 225
Study 34220819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of PCV13
Number of subjects: 225
Study 36273160 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:100 PI diluted sitz bath
Number of subjects: 268
Study 36273160 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:200 PI diluted sitz bath
Number of subjects: 268
Study 36273160 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:300 PI diluted sitz bath
Number of subjects: 268
Study 36273160 — intervention group
Group type: COMPARATOR
Intervention: Perianal cleaning care
Number of subjects: 268
Study 36273160 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 268
Study 34679101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (resistance and aerobic exercises, 3 times per week for 6 months)
Number of subjects: 101
Study 34679101 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 101
Study 34855329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1077
Study 34855329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1077
Study 34855329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1077
Study 34899398 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month interactive behavioral modification intervention (INT) with guided text message feedback (GTF)
Number of subjects: 56
Study 34899398 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term feedback group (LT-GTF) continuing GTF for another nine months
Number of subjects: 56
Study 34899398 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term feedback group (ST-GTF) that stopped receiving GTF
Number of subjects: 56
Study 34899398 — intervention group
Group type: COMPARATOR
Intervention: Non-directive wellness education control (CON)
Number of subjects: 56
Study 33227803 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily probiotic milk (once daily)
Number of subjects: 487
Study 33227803 — intervention group
Group type: EXPERIMENTAL
Intervention: Triweekly probiotic milk (3 days a week)
Number of subjects: 487
Study 33227803 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk (without probiotics)
Number of subjects: 487
Study 36447243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ECV19 (20 μg RBD)
Number of subjects: 229
Study 36447243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ECV19 (10 μg RBD)
Number of subjects: 229
Study 36447243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 34948597 — intervention group
Group type: EXPERIMENTAL
Intervention: Images containing vapor and/or a device or e‐liquid
Number of subjects: 200
Study 34948597 — intervention group
Group type: EXPERIMENTAL
Intervention: Images from warning labels
Number of subjects: 200
Study 32353544 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR
Number of subjects: 300
Study 32353544 — intervention group
Group type: COMPARATOR
Intervention: BUP-SL
Number of subjects: 300
Study 35449351 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led stewardship program for appropriate use of acid suppression therapy
Number of subjects: 197
Study 32242396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingqi Huangban granule (LQHB) plus intravitreal ranibizumab (IVR) injections
Number of subjects: 60
Study 32242396 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) injections
Number of subjects: 60
Study 34504129 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation with alternating currents stimulation
Number of subjects: 0
Study 34504129 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 34504129 — intervention group
Group type: COMPARATOR
Intervention: Patients with optic nerve damage before treatment
Number of subjects: 0
Study 32534080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly absorbable polyglactin 910 (Vicryl Rapide)
Number of subjects: 105
Study 32534080 — intervention group
Group type: COMPARATOR
Intervention: Nylon (Ethilon)
Number of subjects: 105
Study 36327345 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer based cognitive therapy (CBCT)
Number of subjects: 60
Study 36327345 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT + Mediterranean equivalent diet (MED)
Number of subjects: 60
Study 36327345 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT + MED + Exercise regime
Number of subjects: 60
Study 36327345 — intervention group
Group type: COMPARATOR
Intervention: Health awareness instructions (Control)
Number of subjects: 60
Study 33233717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention (integrating face-to-face sessions with a web-based program)
Number of subjects: 0
Study 33233717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention
Number of subjects: 0